Hepatitis C virus infection is a global health problem. There is tremendous advancements in the treatment of chronic hepatitis C in the past two decades. Many new knowledgement in this research area and important treatment strategies are actually discovered by experts from the Asia-Pacific regions including Taiwan. In this review, we will briefly review the epidemiology of hepatitis C virus infection, current standard-of-care for patients with chronic hepatitis C, the role of hepatitis C viral genotype and on-treatment viral kinetics in the individualization of therapy. Finally we will introduce new direct-acting anti-viral-based triple therapy for patients with hepatitis C virus genotype 1 infection.